Shuttle Pharmaceuticals Files S-1/A Update

TL;DR

Shuttle Pharma dropped an S-1/A update on Oct 18th - check financials for Q2 2024.

AI Summary

Shuttle Pharmaceuticals Holdings, Inc. filed an S-1/A on October 18, 2024, detailing its financial status and business operations. The company, located in Gaithersburg, MD, is in the pharmaceutical preparations industry. The filing provides financial data for periods ending June 30, 2024, and December 31, 2023, including details on related and non-related party transactions.

Why It Matters

This S-1/A filing provides updated financial information and disclosures for Shuttle Pharmaceuticals, which is crucial for investors to assess the company's current financial health and strategic direction.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1/A, there's inherent risk associated with clinical trials, regulatory approvals, and market adoption, which are not detailed in this specific filing excerpt.

Key Numbers

• 2024-06-30 — Financial Period End (Most recent financial data available in excerpt)
• 2023-12-31 — Financial Period End (Previous year-end financial data)

Key Players & Entities

• Shuttle Pharmaceuticals Holdings, Inc. (company) — Filer
• 20241018 (date) — Filing Date
• Gaithersburg, MD (location) — Business Address
• 2834 (industry_code) — Standard Industrial Classification
• 333-282231 (filing_number) — SEC File Number
• 2024-06-30 (date) — Financial Period End
• 2023-12-31 (date) — Financial Period End

FAQ

Key Financial Figures

• $0.00001 — he "Shares") of common stock, par value $0.00001 per share ("common stock"), or pre-fund
• $1 — and one accompanying Common Warrant is $1.11, which is the last reported sale pri
• $1.11 — se price of the Common Warrants will be $1.11. The final public offering price per Sh
• $0 — d to the public in this offering, minus $0.001, and the exercise price of each Pre
• $0.001 — rice of each Pre-Funded Warrant will be $0.001 per share. The Pre-Funded Warrants will
• $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underly

Filing Documents

• forms-1a.htm (S-1/A) — 3837KB
• ex1-1.htm (EX-1.1) — 71KB
• ex4-6.htm (EX-4.6) — 116KB
• ex4-7.htm (EX-4.7) — 111KB
• ex5-1.htm (EX-5.1) — 20KB
• ex10-61.htm (EX-10.61) — 283KB
• ex23-1.htm (EX-23.1) — 5KB
• ex107.htm (EX-FILING FEES) — 60KB
• forms-1_001.jpg (GRAPHIC) — 30KB
• forms-1_002.jpg (GRAPHIC) — 87KB
• forms-1_003.jpg (GRAPHIC) — 38KB
• forms-1_004.jpg (GRAPHIC) — 136KB
• forms-1_005.jpg (GRAPHIC) — 39KB
• forms-1_006.jpg (GRAPHIC) — 40KB
• forms-1_007.jpg (GRAPHIC) — 36KB
• forms-1_008.jpg (GRAPHIC) — 46KB
• forms-1_009.jpg (GRAPHIC) — 11KB
• forms-1_010.jpg (GRAPHIC) — 21KB
• forms-1_011.jpg (GRAPHIC) — 99KB
• ex5-1_001.jpg (GRAPHIC) — 13KB
• 0001493152-24-041510.txt ( ) — 17516KB
• shph-20240630.xsd (EX-101.SCH) — 78KB
• shph-20240630_cal.xml (EX-101.CAL) — 81KB
• shph-20240630_def.xml (EX-101.DEF) — 478KB
• shph-20240630_lab.xml (EX-101.LAB) — 637KB
• shph-20240630_pre.xml (EX-101.PRE) — 557KB
• forms-1a_htm.xml (XML) — 2756KB

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 62 MANAGEMENT 74 EXECUTIVE AND DIRECTOR COMPENSATION 83 BENEFICIAL OWNERSHIP OF SECURITIES 86 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 87 CAPITALIZATION 88

DILUTION

DILUTION 89 DIVIDEND POLICY 9 0 DESCRIPTION OF CAPITAL STOCK 90 DESCRIPTION OF SECURITIES WE ARE OFFERING 95 PLAN OF DISTRIBUTION 97 LEGAL MATTERS 99 EXPERTS 99 WHERE YOU CAN FIND MORE INFORMATION 99 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS The registration statement of which this prospectus forms a part and which we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the heading "Where You Can Find More Information" before making your investment decision. You should rely only on the information provided in this prospectus, in any prospectus supplement or in a related free writing prospectus, or documents to which we otherwise refer you. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copi

View Full Filing

View this S-1/A filing on SEC EDGAR